Navigation Links
GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools
Date:3/5/2009

GERMANTOWN, Md., March 5 /PRNewswire/ -- GeneCopoeia announces the launch of a suite of miRNA functional analysis reagents and tools. They include 1) miExpress(TM) vector based precursor miRNA expression clones; 2) miTarget(TM) miRNA target sequence (3' UTR) expression clones; and 3) All-in-One(TM) miRNA RT-qPCR system.

Constructed in a lentiviral vector system, miExpress(TM) precursor miRNA expression clone collections cover all known miRNAs for human (750), mouse (450), and rat (270). These lentiviral vector based expression constructs allow efficient transduction of miRNAs into dividing and non-dividing cells transiently or stably, and can be used for in vitro assays and in vivo animal studies. The transduction efficiencies are monitored by the expression level of an indicator/reporter gene.

miTarget(TM) miRNA target sequence (3' UTR) expression clones cover genome-wide human, mouse and rat genes. These expression ready constructs are made in a mammalian expression vector system with dual reporter genes, which provides a ready-for-use and single vector solution for both transcriptional regulation reporting and an internal control for normalization reporting.

In addition to the two types of expression constructs, GeneCopoeia plans to launch All-in-One(TM) miRNA RT-qPCR system in the next few weeks. This system consists of a reverse transcription kit, a SYBR green RT-qPCR master mix kit, and a complete set of validated primers for human, mouse, and rat miRNAs, which allows specific and sensitive quantification of miRNAs individually or in an array format.

GeneCopoeia also plans to release soon a set of vector based miRNA suppressor construct products currently in development. Together with other miRNA products aforementioned, this product line will provide a complete set of tools and solutions for miRNA functional analysis.

For more information, please visit: http://www.genecopoeia.com/product/mirna/

About GeneCopoeia

GeneCopoeia, Inc is a Maryland, US, based manufacturer and provider of a wide range of biological and biomedical research reagent products as well as a full spectrum of custom services. GeneCopoeia, together with its joint venture, FulenGen, has produced the largest number of full-sequence-verified human and mouse full length protein coding ORF cDNA clones, which are offered to customers in more than 80 vectors with a choice of over 50 different fusion tags.

    Sun Lu, Ph. D.
    19520 Amaranth Drive
    Germantown, Maryland 20874
    USA
    Tel: 301-515-6982
    Fax: 301-515-6983
    marketing@genecopoeia.com
    www.genecopoeia.com


'/>"/>
SOURCE GeneCopoeia, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
2. Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells
3. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
4. Max Muscle Introduces First-Ever Probiotics Protein Bar
5. bioMerieux Introduces Surveillance Tool to Fight Healthcare-Associated Infections
6. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
7. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
8. Elsevier Introduces Breakthrough Technology Intelligence Solution for Accelerating R&D and Innovation in Europe
9. Cell Biosciences Introduces Kits for Oncoprotein Analysis
10. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
11. GEMS Introduces Ultrasonic Continuous Liquid Level Sensor for Challenging Fluid Measurement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... NJ (PRWEB) , ... February 09, 2016 , ... ... Dorman, former Vice President for Public Policy for the National Organization for Rare ... patient advocacy groups to ensure their voices are heard throughout the drug regulatory ...
(Date:2/9/2016)... LEXINGTON, Massachusetts , February 9, 2016 ... Enables Children to Take Part in Life-Changing Camp ... announcing a new initiative designed to positively affect the lives of ... rare disease care. --> SHPG ) is announcing a ... with rare diseases, as well as the future of rare disease ...
(Date:2/8/2016)... Feb. 8, 2016 Should antibiotic bone cement ... products to prevent infection after standard total hip or ... at ECRI Institute have been fielding a lot lately. ... Your Bottom Line?" --> "Antibiotic ... --> While there isn,t a ...
(Date:2/8/2016)... ... February 08, 2016 , ... Thomas ... is the Executive Vice President for Corporate Services and the Chief Financial Officer ... Payable, Payroll, Billing Operations, Treasury, Managed Care Contracting, Supply Chain, and Investments. , ...
Breaking Biology Technology:
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
(Date:1/25/2016)...   Unisys Corporation (NYSE: UIS ) today announced ... International Airport, New York City , to help ... to enter the United States using passports ... pilot testing of the system at Dulles last year. The ... during January 2016. --> pilot testing of the ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
Breaking Biology News(10 mins):